August 30, 2016 10:26 AM EDT

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

John Carroll

Editor & Founder

San Diego-based Neurocrine Biosciences announced that it has filed their NDA on a new drug for tardive dyskinesia today, but the company isn’t waiting for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Neu­ro­crine steers its ‘break­through’ tar­dive dysk­i­ne­sia drug to an FDA de­ci­sion

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision